-
Tytuł:
-
Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study.
-
Autorzy:
-
Kristensen FP; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark .; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Christensen DH; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Callaghan BC; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.; Department of Neurology, University of Michigan, Ann Arbor, MI.
Kahlert J; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Knudsen ST; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Sindrup SH; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.; Department of Neurology, Odense University Hospital, Odense, Denmark.
Feldman EL; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.; Department of Neurology, University of Michigan, Ann Arbor, MI.
Østergaard L; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.; Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark.
Andersen H; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.; Department of Neurology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Jensen TS; The International Diabetic Neuropathy Consortium, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.; Department of Neurology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Sørensen HT; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Thomsen RW; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
-
Źródło:
-
Diabetes care [Diabetes Care] 2020 Dec; Vol. 43 (12), pp. 2945-2952. Date of Electronic Publication: 2020 Sep 30.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Alexandria Va : American Diabetes Association
Original Publication: New York, American Diabetes Assn.
-
MeSH Terms:
-
Diabetes Mellitus, Type 2/*complications
Diabetic Neuropathies/*chemically induced
Diabetic Neuropathies/*epidemiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects
Adult ; Aged ; Cohort Studies ; Denmark ; Diabetes Mellitus, Type 2/epidemiology ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Incidence ; Male ; Middle Aged ; Propensity Score ; Proportional Hazards Models ; Risk Factors
-
Substance Nomenclature:
-
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
-
Entry Date(s):
-
Date Created: 20201001 Date Completed: 20210514 Latest Revision: 20210514
-
Update Code:
-
20240105
-
DOI:
-
10.2337/dc20-1004
-
PMID:
-
32998990
-
Objective: Statins may reduce the risk of diabetic polyneuropathy (DPN) as a result of lipid-lowering and anti-inflammatory effects, but statins have also been associated with neurotoxicity. We examined whether statin therapy affects the risk of DPN.
Research Design and Methods: We identified all Danish patients with incident type 2 diabetes during 2002-2016. New users initiated statins between 180 days before and 180 days after their first diabetes record, while prevalent users had initiated statins before that period. Patients were followed for incident DPN using validated hospital diagnosis codes, starting 180 days after their first diabetes record. Cox proportional hazard analysis was used to compute adjusted hazard ratios (aHRs) for DPN.
Results: The study cohort comprised 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers; median follow-up time was 6.2 years (interquartile range 3.4-9.6). The incidence rate of DPN events per 1,000 person-years was similar in new users (4.0 [95% CI 3.8-4.2]), prevalent users (3.8 [3.6-3.9]), and nonusers (3.8 [3.7-4.0]). The aHR for DPN was 1.05 (0.98-1.11) in new users and 0.97 (0.91-1.04) in prevalent users compared with statin nonusers. New users had a slightly increased DPN risk during the first year (1.31 [1.12-1.53]), which vanished after >2 years of follow-up. Findings were similar in on-treatment and propensity score-matched analyses and with additional adjustment for pretreatment blood lipid levels.
Conclusions: Statin therapy is unlikely to increase or mitigate DPN risk in patients with type 2 diabetes, although a small acute risk of harm cannot be excluded.
(© 2020 by the American Diabetes Association.)
